Detail for Voriconazole
Basic Information
DrugID 104
DrugName Voriconazole
DrugDetail Voriconazole (VFEND, Pfizer) is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. These are generally seen in patients who are immunocompromised, and include invasive candidiasis, invasive aspergillosis, and certain emerging fungal infections.

http://en.wikipedia.org/wiki/Voriconazole

Indication For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.

http://www.drugbank.ca/drugs/DB00582

Structure Click to see the orginal picture.
Interaction
Drug Name PMIDLink Reference
Amiodarone Guo Q, Sun S, Li Y, Yu J, Shi C. (2008) In vitro interactions between azoles and amiodarone against clinical Candida albicans. Int J Antimicrob Agents. 31(1):88-90.
Amphotericin B Li H, Lu Q, Wan Z, Zhang J. (2010) In vitro combined activity of amphotericin B, caspofungin andagainst clinical isolates of Trichosporon asahii. Int J Antimicrob Agents. 35(6):550-2.
Amphotericin B C��rdoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG.. (2008) In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 31(2):171-4.
Anidulafungin Meletiadis J, Pournaras S, Roilides E, Walsh TJ. (2010) Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 54(2):602-9.
Anidulafungin Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, Ostrosky-Zeichner L. (2005) In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother. 49(8):3572-4.
Anidulafungin Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, Schaufele RL, Sein T, Avila NA, Bacher J, Walsh TJ. (2009) Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin andby Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 53(6):2382-91.
Caspofungin Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E, Walsh TJ. (2008) Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrob Agents Chemother. 52(6):2196-204.
Caspofungin Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, Rodriguez-Tudela JL. (2005) Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Chemother. 49(3):1232-5.
Caspofungin Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Oz Y. (2010) Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods. Antimicrob Agents Chemother. 54(5):2244-7.
Caspofungin Li H, Lu Q, Wan Z, Zhang J. (2010) In vitro combined activity of amphotericin B, caspofungin andagainst clinical isolates of Trichosporon asahii. Int J Antimicrob Agents. 35(6):550-2.
Ethambutol Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Flucytosine Schwarz P, Dromer F, Lortholary O, Dannaoui E. (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother. 47(10):3361-4.
Itraconazole Garcia-Effron G, Mellado E, Gomez-Lopez A, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. (2005) Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus. Antimicrob Agents Chemother. 49(5):2119-21.
Lovastatin Chamilos G, Lewis RE, Kontoyiannis DP. (2006) Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother. 50(1):96-103.
Micafungin Heyn K, Tredup A, Salvenmoser S, M��ller FM. (2005) Effect ofcombined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother. 49(12):5157-9.
Micafungin Serena C, Fern��ndez-Torres B, Pastor FJ, Trilles L, Laz��ra Mdos S, Nolard N, Guarro J. (2005) In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob Agents Chemother. 49(7):2994-6.
Pyrazinamide Cordeiro Rde A, Brilhante RS, Rocha MF, Medrano DJ, Monteiro AJ, Tavares JL, de Lima RA, de Camargo ZP, Sidrim JJ. (2009) In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii. Int J Antimicrob Agents. 34(3):278-80.
Terbinafine Ortoneda M, Capilla J, Pastor FJ, Pujol I, Yustes C, Serena C, Guarro J. (2004) In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother. 48(7):2727-9.
Terbinafine Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. (2004) In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis. 48(1):69-71.
Terbinafine Dannaoui E, Afeltra J, Meis JF, Verweij PE; Eurofung Network. (2002) In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 46(8):2708-11.
Terbinafine C��rdoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG.. (2008) In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. Feb;31(2):171-4.
Terbinafine Meletiadis J, Mouton JW, Meis JF, Verweij PE. (2003) In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 47(1):106-17.
FK506 Sun S., Li Y., Guo Q.J., Shi C.W., Yu J.L., Ma L. (2008) In vitro interactions between tacrolimus and Azoles against Candida albicans determined by different methods. Antimicrobial Agents and Chemotherapy 52:409-417. DOI: 10.1128/aac.01070-07.
Micafungin Nishi I., Sunada A., Toyokawa M., Asari S., Iwatani Y. (2009) In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species (vol 15, pg 1, 2009). Journal of Infection and Chemotherapy 15:123-124. DOI: 10.1007/s10156-009-0002-7
Terbinafine Weig M., Muller F.M.C. (2001) Synergism ofand terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrobial Agents and Chemotherapy 45:966-968.
Cyclosporine A Li Y., Sun S.J., Guo Q.J., Ma L., Shi C.W., Su L.Q., Li H.J. (2008) In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. Journal of Antimicrobial Chemotherapy 61:577-585. DOI: 10.1093/jac/dkm493.
Flucytosine Schwarz P., Dromer F., Lortholary O., Dannaoui E. (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrobial Agents and Chemotherapy 47:3361-3364. DOI: 10.1128/aac.47.10.3361-3364.2003
Phenelzine 1
Target
PathWay
PathWay Name Path Picture
Steroid biosynthesis - Reference pathway (KO)